EYPT

+ Watchlist + Portfolio

EyePoint, Inc.

Regulated industry Physical productsTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $3.23
52-Week Range: $3.10 – $19.11
Market Cap: $280.19M
P/E (TTM): —
EPS (TTM): -3.75
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 8.21
PEG Ratio: —
Return on Equity: -148.70%
Return on Assets: -74.85%
Gross Margin: 0.00%
Operating Margin: -19207.10%
Profit Margin: 0.00%
Current Ratio: 4.50
Debt/Equity: 0.13
Total Debt: $22.37M
Free Cash Flow: $-155.01M
Revenue Growth: -90.50%
Earnings Growth: —
Enterprise Value: $122.08M

EYPT Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$41.40M	$46.02M	$43.27M	$31.37M
Cost of Revenue	$8.33M	$4.63M	$3.71M	$2.07M
Gross Profit	$33.08M	$41.39M	$39.56M	$29.30M
Research & Development	$49.64M	$64.66M	$132.93M	$221.04M
Selling, General & Admin	$60.32M	$51.79M	$52.49M	$51.70M
Operating Expenses	$112.02M	$116.45M	$185.41M	$272.74M
Operating Income	-$78.94M	-$75.07M	-$145.85M	-$243.43M
EBITDA	-$96.62M	-$69.00M	-$129.23M	-$229.34M
Pretax Income	-$102.25M	-$70.71M	-$130.78M	-$231.68M
Income Tax	$0.00	$83.00K	$90.00K	$279.00K
Net Income	-$102.25M	-$70.80M	-$130.87M	-$231.96M
Diluted EPS	-2.74	-1.82	-2.32	-3.17
Diluted Shares	37.32M	38.90M	56.30M	73.25M

EYPT Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$95.63M	$281.26M	$99.70M	$101.82M
Receivables	$15.50M	$805.00K	$607.00K	$651.00K
Inventory	$2.89M	$3.91M	$2.31M	$1.81M
Current Assets	$172.81M	$344.80M	$383.31M	$328.65M
Total Assets	$180.36M	$355.18M	$418.46M	$364.00M
Current Liabilities	$34.54M	$63.26M	$49.05M	$37.02M
Long-Term Debt	$29.31M	—	—	—
Total Debt	$45.77M	$4.91M	$21.86M	$20.77M
Total Liabilities	$83.99M	$88.86M	$81.96M	$57.88M
Retained Earnings	-$671.35M	-$742.15M	-$873.02M	-$1.10B
Shareholders' Equity	$96.37M	$266.32M	$336.50M	$306.11M
Working Capital	$138.27M	$281.54M	$334.26M	$291.63M

EYPT Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$65.00M	$1.88M	-$126.23M	-$240.11M
Capital Expenditure	-$2.15M	-$3.48M	-$4.05M	-$3.28M
Free Cash Flow	-$67.16M	-$1.61M	-$130.28M	-$243.39M
Depreciation & Amortisation	$2.45M	$464.00K	$1.54M	$2.31M
Stock-Based Compensation	$14.18M	$12.06M	$36.74M	$27.87M
Investing Cash Flow	-$17.27M	-$3.31M	-$219.35M	$68.58M
Financing Cash Flow	-$690.00K	$187.07M	$164.02M	$173.65M
Net Change in Cash	-$82.96M	$185.63M	-$181.56M	$2.12M

EYPT Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$24.45M	$5.33M	$966.00K	$620.00K	$696.00K	$507.00K
Cost of Revenue	$805.00K	$165.00K	$721.00K	$375.00K	$528.00K	$0.00
Gross Profit	$23.65M	$5.17M	$245.00K	$245.00K	$168.00K	$507.00K
Research & Development	$58.57M	$55.50M	$47.75M	$59.21M	$72.15M	$83.61M
Selling, General & Admin	$13.91M	$11.90M	$14.52M	$11.38M	$15.25M	$14.27M
Operating Expenses	$72.48M	$67.39M	$62.27M	$70.59M	$87.39M	$97.89M
Operating Income	-$48.84M	-$62.23M	-$62.02M	-$70.34M	-$87.23M	-$97.38M
EBITDA	-$48.34M	-$61.69M	-$61.45M	-$57.86M	-$86.59M	-$96.69M
Pretax Income	-$45.20M	-$59.33M	-$59.73M	-$67.42M	-$84.88M	-$94.47M
Income Tax	$0.00	$93.00K	$0.00	$186.00K	-$50.00K	$0.00
Net Income	-$45.20M	-$59.43M	-$59.73M	-$67.61M	-$84.83M	-$94.47M
Diluted EPS	-0.65	-0.85	-0.85	-0.81	-0.99	-1.09
Diluted Shares	69.77M	69.93M	70.17M	83.03M	86.00M	86.54M

EYPT Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$85.16M	$71.14M	$74.58M	$101.82M	$77.71M	$110.46M
Receivables	$442.00K	$625.00K	$1.04M	$651.00K	$1.16M	$86.00K
Inventory	$2.13M	$2.68M	$2.11M	$1.81M	$1.25M	$1.88M
Current Assets	$326.98M	$265.25M	$216.11M	$328.65M	$249.50M	$188.82M
Total Assets	$362.56M	$301.15M	$251.69M	$364.00M	$288.22M	$228.19M
Current Liabilities	$41.68M	$33.17M	$30.09M	$37.02M	$37.46M	$41.94M
Total Debt	$24.08M	$21.82M	$21.30M	$20.77M	$20.23M	$19.81M
Total Liabilities	$64.17M	$55.14M	$51.51M	$57.88M	$57.74M	$61.78M
Retained Earnings	-$918.21M	-$977.64M	-$1.04B	-$1.10B	-$1.19B	-$1.28B
Shareholders' Equity	$298.40M	$246.01M	$200.18M	$306.11M	$230.47M	$166.41M
Working Capital	$285.31M	$232.08M	$186.01M	$291.63M	$212.04M	$146.87M

EYPT Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$53.12M	-$62.59M	-$59.35M	-$65.05M	-$80.55M	-$62.35M
Capital Expenditure	-$276.00K	-$1.22M	-$798.00K	-$986.00K	-$997.00K	-$1.20M
Free Cash Flow	-$53.40M	-$63.81M	-$60.15M	-$66.03M	-$81.55M	-$63.55M
Depreciation & Amortisation	$497.00K	$538.00K	$576.00K	$698.00K	$636.00K	$690.00K
Stock-Based Compensation	$7.82M	$6.88M	$6.43M	$6.75M	$11.64M	$10.40M
Investing Cash Flow	$39.52M	$48.34M	$55.38M	-$74.67M	$59.05M	$75.10M
Financing Cash Flow	-$951.00K	$238.00K	$7.40M	$166.96M	-$2.61M	$19.99M
Net Change in Cash	-$14.55M	-$14.02M	$3.43M	$27.24M	-$24.11M	$32.75M

Market Snapshot

About

EyePoint Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing therapeutics for serious eye disorders. The company's proprietary Durasert technology platform enables sustained, controlled release of medication directly into the eye, providing long-term therapeutic effect from a single administration. EyePoint markets YUTIQ for chronic non-infectious uveitis and DEXYCU for post-surgical inflammation, while developing additional product candidates for retinal diseases including wet age-related macular degeneration and diabetic macular edema. The company's approach aims to reduce treatment burden for patients with chronic eye conditions.